The Johns Hopkins Center for Psychedelic and Consciousness Research is leading the way in exploring innovative treatments using psilocybin. The molecular structure of psilocybin, a naturally occurring psychedelic compound found in 'magic mushrooms,' allows it to penetrate the central nervous system and the scientific and medical experts are just beginning to understand its effects on the brain and mind and its potential as therapeutics for mental illnesses.
Backed by $17 million of funding, researchers build on previous work and expand research on psychedelics for illness and wellness: (1) to develop new treatments for a wider variety of psychiatric and behavioral disorders with the aspiration of treatments tailored to the specific needs of individual patients and (2) to expand research in healthy volunteers with the ultimate aspiration of opening new ways to support human thriving.
Related Links:
Psychedelic Treatment with Psilocybin Relieves Major Depression, Study Shows
In a small study of adults with major depression, Johns Hopkins Medicine researchers report that two doses of the psychedelic substance psilocybin, given with supportive psychotherapy, produced rapid and large reductions in depressive symptoms, with most participants showing improvement and half of study participants achieving remission through the four-week follow-up.
Read the News Release
Psilocybin Research and Potential
Roland Griffiths, Ph.D., presented a TEDMED talk in 2015 about the therapeutic and consciousness potential of psilocybin. Research to date demonstrate safety of psilocybin in regulated spaces facilitated by medical team over a series of guided sessions; and as a part of cognitive behavioral therapy, psilocybin helps in reducing anxiety in some cancer patients, and in facilitating smoking cessation for some.
Watch Video
The Neuroscience of Psychedelic Drugs, Music and Nostalgia
With controlled psychedelic substances, there is a potential to alter the entire brain for a period of time and thus provide relief from negative emotions that cloud the mind. Capturing this controlled relief, Dr Frederick Barrett's research suggests that, under the right conditions, psychedelics may have the potential to treat a wide range of mood and substance disorders.
Watch Video
Center Highlights:
2000
Regulatory approval to resume psychedelics research
A group of Johns Hopkins researchers was the first to obtain regulatory approval in the United States to resume research with psychedelics in healthy volunteers who had no previous experience with psychedelics.
2006
Milestone study launching the revival of psilocybin research
The publication "Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance" on the safety and enduring positive effects of a single dose of psilocybin is widely considered the landmark study that sparked a renewal of psychedelic research world-wide.
See More Academic Papers
2008
Guidelines for safety
The Center’s team emphasizes safety as a cornerstone of psychedelics research. These recommended techniques in this publication, "Human hallucinogen research: guidelines for safety," have been adopted by others in the field.
Read the Paper
2014
'Magic mushrooms' help longtime smokers quit
Johns Hopkins researchers report that a small number of longtime smokers who had failed many attempts to drop the habit did so after a carefully controlled and monitored use of psilocybin, the active hallucinogenic agent in so-called "magic mushrooms,” in the context of a cognitive behavioral therapy treatment program.
Read the News Release
2016
Psilocybin eases existential anxiety in people with life threatening cancer
In a small double-blind study, Johns Hopkins researchers report that a substantial majority of people suffering cancer-related anxiety or depression found considerable relief for up to six months from a single large dose of psilocybin — the active compound in hallucinogenic “magic mushrooms.”
Read the News Release
2018
Reclassification recommendation for psilocybin
In an evaluation of the safety and abuse research on the drug in hallucinogenic mushrooms, Johns Hopkins researchers suggest that if it clears phase III clinical trials, psilocybin should be re-categorized from a schedule I drug—one with no known medical potential—to a schedule IV drug such as prescription sleep aids, but with tighter control.
Read the News Release
2019
Psychedelic use may lead to treatments for alcohol abuse
Online survey of over 300 people with Alcohol Use Disorder reported reducing or abstaining alcohol use after taking a psychedelic drug such as psilocybin, LSD or DMT. This study adds to growing evidence for supporting further investigation of psychedelic-assisted treatment for alcoholism or substance abuse.
Read the Paper
Johns Hopkins launches center for psychedelic research
A group of private donors has given $17 million to start the Center for Psychedelic and Consciousness Research at Johns Hopkins Medicine, making it what’s believed to be the first such research center in the U.S., and the largest research center of its kind in the world. In the absence of federal funding for such therapeutic research in people, the new center will rely on the gifts announced today to advance the emerging field of psychedelics for therapies and wellness.
Read the News Release
2020
Psychedelic Drug Psilocybin Tamps Down Brain’s Ego Center
The brain scans after psilocybin use showed that the claustrum was less active, meaning the area of the brain believed responsible for setting attention and switching tasks is turned down when on the drug. The researchers say that this ties in with what people report as typical effects of psychedelic drugs, including feelings of being connected to everything and reduced senses of self or ego.
Read the News Release
The Johns Hopkins Center for Psychedelic and Consciousness Research
At the Center, researchers focus on how psychedelics affect behavior, mood, cognition, brain function, and biological markers of health. Upcoming studies will determine the effectiveness of psilocybin as a new therapy for opioid addiction, Alzheimer's disease, post-traumatic stress disorder (PTSD), post-treatment Lyme disease syndrome (formerly known as chronic Lyme disease), anorexia nervosa and alcohol use in people with major depression.
Visit the Center and Meet the Experts
